Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Anti-Obesity Agent Belviq Approved in US, to Be Launched in Jan. 2013: Eisai
July 2, 2012
- Merck Serono No. 1 in Infertility Treatment Market through Ninkatsu Image Strategy
July 2, 2012
- M3, Mediscience, MIC Medical Consider Capital, Operational Alliance to Establish 650 CRAs Structure
June 29, 2012
- Teva Pharma to Streamline Overlapping Products in 3 years: President Shimada
June 29, 2012
- Bayer Yakuhin to Transfer 3 Established Products to FFP
June 29, 2012
- NDA Filed for Gout Treatment Topiroxostat: Fuji Yakuhin, Sanwa Kagaku
June 29, 2012
- FDA Accepts NDA for Ospemifene for VVA: Shionogi
June 29, 2012
- AnGes MG Obtains Exclusive Rights for Vaccine for Precancerous Condition of the Cervix in China
June 28, 2012
- Takeda Ranked No. 1 in Medical Category for 5th Year in a Row: Popularity Rankings for Career Change
June 28, 2012
- DSP Launches Myslee Generic on June 28
June 28, 2012
- Eisai to Make Full-Scale Entry into Russian Market; Antiepileptic Agent Obtains Approval
June 28, 2012
- Yoshindo to Accumulate Know-How to Develop Biopharmaceutical Products through Contract Manufacturing
June 28, 2012
- Astellas Files MAA for Anti-Androgen Agent MDV3100 in Europe
June 28, 2012
- Chugai Applies for Tarceva for NSCLC First-Line Therapy
June 28, 2012
- Takata Seiyaku to Market 3 Products from Shionogi
June 28, 2012
- MSs Want “Client Visits by MRs” for Generic Promotion: Toho Pharmaceutical Survey
June 27, 2012
- Large Number of GEs Could Become Serious Issue: Alfresa Logistics Chief Fukujin
June 27, 2012
- Takeda to Market Iron Deficiency Anemia Drug in Europe
June 27, 2012
- DSP to Ship Almarl under New Brand Name from Mid-July
June 27, 2012
- Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey
June 27, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…